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No epidemiological data exist so far on invasive mucormycosis (IM) in Polish hematopoietic cell transplantation (HCT) and pediatric 
hemato-oncology (PHO) centers. The objective of this study was to analyze the incidence, clinical course, therapy, and outcome 
of IM in pediatric and adult patients undergoing HCT and children with hemato-oncological diseases in Poland. A total number of 
12425 at-risk patients were retrospectively analyzed, and the period between 2010 and 2019 was included. Patients were analyzed 
in three groups: nontransplant children with malignancies, children undergoing HCT, and adults after HCT. Twenty-one patients were 
diagnosed with IM, including 15 children (10 non-HCT, 5 HCT) and 6 HCT adults. Proven IM was confirmed in 18 patients, probable in 
2 patients, and possible in 1 patient. Proven IM was diagnosed in 7.1% of all patients with invasive fungal diseases (IFDs), including 8.1% 
among PHO patients, 5.4% among pediatric HCT patients, and 7.0% among adult HCT patients. Clinically, pneumonia was diagnosed 
in 10 (47.6%) patients, involvement of the paranasal sinuses was found in 3 (14.3%) patients, gastrointestinal disease was noted in 
2 (9.5%) patients, and disseminated mucormycosis was found in 6 (28.6%) patients. The probability of overall survival in IM patients 
was 0.50 ± 0.11. Infection-related mortality (IRM) was 10% for pediatric nontransplant IM patients and 82% for transplant IM (pediatric 
+ adult) patients (p = 0.004). Among the transplant patients, all adults died within 120 days. IRM for pediatric HCT patients was 60% 
(p = 0.038). The only prognostic factor was HCT, which adversely influenced survival in IM patients.
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Introduction
Invasive mucormycosis (IM) is responsible for 
8% of invasive fungal diseases (IFDs) in patients 
with hematological malignancies (HMs) or after 
hematopoietic cell transplantation (HCT), and its 
incidence is significantly increasing in these cohorts. 
These two groups of patients, together with diabetes 
patients, are regarded to be at the highest risk of 
development of IM [1, 2, 3].
Mucormycetes (previously: Zygomycetes; recently 
proposed: Entomophthorales [4]) organisms are highly 
aggressive, filamentous, ubiquitous, fast-growing, 
broad aseptate fungi, which are unique among 
filamentous fungi because of their disproportionately 
high capacity to cause devastating disease in patients 
regardless of underlying conditions [5, 6].
The activity of Mucormycetes is characterized by 
angioinvasion and tissue invasion, which leads 
to a rapid and progressive infection. The clinical 
presentations are pulmonary, gastrointestinal, 
soft tissue, paranasal (sino-orbital), and cerebral 
mucormycoses, with possible evolution into 
disseminated disease [6, 7].
No epidemiological data exist so far about IM in Polish 
HM/HCT centers. The aim of this paper was to present 
the analysis of incidence, clinical course, therapy, and 
outcome of IM in children and adults either with hemato-
oncological diseases or undergoing HCT in Poland.
Patients and methods
Design of the study
Collection and analysis of data were performed 
as part of the project on analysis of “Infections in 
pediatric hematology, oncology, and hematopoietic 
transplantation” (“iPhot”) in the respective 2-year-
period editions of 2013, 2015, 2017, and 2019; this 
study was devoted to the analysis of the incidence 
and outcome of fungal, bacterial, and viral infections 
in HCT/pediatric hemato-oncology (PHO) patients. 
This project was widened to include the adult 
hematopoietic transplant setting for the period 2012–
2014. The overall results of this national project were 
presented elsewhere [8, 9, 10].
Additionally, published literature and abstracts from 
national hematology meetings (Polish Society of 
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Pediatric Oncology and Hematology [PTOHD], Polish Society 
of Hematology and Transfusion Medicine [PTHiT] and Polish Adult 
Leukemia Group [PALG]) during the period 2010–2012 were 
retrieved and searched for data on infections with mucormycoses in 
hematopoietic transplant, hematology, and PHO settings in Polish 
hematology or HCT settings. Nevertheless, no data on mucormycoses 
for the period 2010–2011 were found in available literature.
Patients
Three groups of patients were included in the study. Group A: 
all consecutive adult patients transplanted (Ad-HCT) between 
January 1, 2012 and December 31, 2014 in 11/13 Polish HCT 
centers for adults, as well as patients after HCT diagnosed with 
mucormycosis between January 1, 2015 and September 30, 2019 in 
7 HCT centers for adults. Group B: all consecutive pediatric patients 
transplanted (Ch-HCT) between January 1, 2012 and December 31, 
2017 in 5/5 pediatric HCT centers, and post-HCT patients diagnosed 
with mucormycosis between January 1, 2018 and July 31, 2019 in 
pediatric HCT centers. Group C: all consecutive children treated 
between January 1, 2012 and December 31, 2017 for malignant 
hematological and nonhematological diseases in 14–16 out of 
18 pediatric oncology centers, as well as children with malignancies 
diagnosed with mucormycosis between January 1, 2018 and July 31, 
2019 in PHO centers. Infections were reported every 2 years by 
each center, and data were verified and analyzed centrally by three 
researchers.
Diagnosis of fungal infections
The diagnosis of IFD was made according to the criteria of the 
European Organization for the Research and Treatment of Cancer/
Mycosis Study Group (EORTC/MSG) as proven, probable, or 
possible in the 2002 and 2008 versions, and finally revised and 
updated according to the new 2019 criteria [11]. All HCT and PHO 
patients were screened with the galactomannan test mainly during 
neutropenia or on the basis of clinically driven indications [8, 9, 10]. 
Mucormycetes-directed polymerase chain reaction (PCR) study was 
not used in the diagnosis for the patients included in this analysis.
Definitions of proven, probable, and possible mucormy-
cosis
Due to the lack of standardized biomarkers specific for Mucormycetes 
during the study period, the definitions of proven, probable, and 
possible IM were modified for the purpose of this study.
Proven IM diagnosis required histopathologic, cytopathologic, or 
direct microscopic examination or positive culture of a specimen 
obtained by biopsy, from the site corresponding to clinical symptoms.
Probable IM diagnosis required the presence of clinical features and 
(i) mycologic evidence or (ii) histopathologic, cytopathologic, or direct 
microscopic examination or positive culture of a specimen obtained 
by biopsy, from the site NOT corresponding to clinical symptoms (e.g., 
clinical and radiological symptoms of invasive fungal pneumonia 
and presence of Mucormycetes in the gastrointestinal tract; with the 
absence of evidences of any other documented infectious etiology).
Possible IM was diagnosed in cases that met the criteria for a host 
factor and a clinical feature but for which mycological evidence was 
not found.
Prophylaxis of fungal infections
Environmental prophylaxis was applied in all the centers according to 
the commonly accepted policy [12, 13]. Children received antifungal 
prophylaxis with fluconazole till 2014. Afterward, posaconazole and 
subsequently voriconazole were introduced in the national program 
of antifungal prophylaxis in children; therefore, from the end of 2014, 
posaconazole or voriconazole were used in high-risk acute leukemia 
patients, in the neutropenic phase after HCT, in the case of graft-
versus-host-disease (GVHD), or in secondary prophylaxis. In the 
adult HCT setting, fluconazole was used for antifungal prophylaxis 
during neutropenia, together with regular screening using serum 
galactomannan level and high-resolution computed tomography 
(HRCT/CT) in case of suspected IFD; from 2015 onward, 
posaconazole or voriconazole were used in case of GVHD.
Data analysis
Clinical characteristics and outcome were performed on all cases 
of mucormycoses reported by the participating centers between 
2010 and 2019. The overall incidence of IM for adults with respect 
to the number of patients treated for malignancy or undergoing 
transplantation was calculated based on the following data: from 
2012 to 2014 from 11 centers; from 2015 to 2019 from 4 centers. 
Similarly, for children, this was calculated based on data from 2012 to 
2017 from 14–16 centers and data from 2018 to 2019 from 3 centers. 
The incidence of IM as a rate of all cases of IFD for adults, with 
respect to the number of patients with IFD, was calculated based on 
data from 2012 to 2014 from 11 centers; while for children, this was 
done based on data from 2012 to 2017 from 14–16 centers.
Infection-related mortality (IRM)
Treatment-related mortality was defined as any death occurring at 
any point after the start of treatment, which did not occur as a result of 
relapse or secondary malignancy. Outcome of infection was regarded 
as positive in case of survival in infected people or negative in case 
of death from infection. IRM was defined as any death that occurred 
in the presence of infection, starting from the day of diagnosis of 
infection. In case of relapse and progression of malignancy, this was 
regarded as the primary cause of death, regardless of concomitant 
infection.
Transplant procedures and unrelated donor matching
For unrelated donors, human leukocyte antigen (HLA) compatibility 
was established for 10 antigens. For matched sibling donors (MSDs), 
HLA compatibility was established for 6 antigens. In case of unrelated 
donors, 10/10 HLA compatibility was regarded as matched unrelated 
donor (MUD), while <10/10 HLA was regarded as mismatched 
unrelated donor (MMUD). Most patients who underwent MUD/
MMUD-HCT received antithymocyte globulin (ATG).
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Statistical analysis
Categorical variables were compared using the chi-square test, 
noncategorical variables were compared using the Mann–Whitney 
U-test. Odds ratios (ORs) and confidence intervals (95% CIs) 
were calculated for the difference in the occurrence of infections 
in the patients. For the analysis of incidence, an infectious event 
was defined as the diagnosis of a first specific infectious disorder. 
Cumulative incidence of infections was calculated, starting from 
the day of transplant in the HCT setting (or the day of diagnosis of 
malignancy in the PHO setting) to the day of the first infection. Death 
was considered the competing event. The Kaplan–Meier method 
was used to determine survival after infection, counting from the 
day of diagnosis of infection. The relationship between death from 
mucormycosis and other variables regarded as risk factors was 
examined using univariate logistic regression: ORs and 95% CIs 
were calculated for each factor. All reported p-values are two-sided; 
p < 0.05 was considered statistically significant.
Results
Demographics
A total number of 21 patients were diagnosed with IM, including 
15/7788 (0.019%) children and 6/5237 (0.011%) adults (OR = 2.9; 
95% CI = 2.0–3.6; p < 0.0001, Tab. I). There were no differences 
in the incidence of mucormycosis between PHO and HCT 
(pediatric + adults) patients (0.017% vs. 0.017%; OR = 1.0; 
95% CI = 0.4–2.2; p = 0.9). The incidence of mucormycosis 
was much higher in pediatric HCT than adult HCT patients 
(0.043% vs. 0.011%; OR = 3.8; 95% CI = 1.1–12.3; p = 0.019). Out of 
21 patients with mucormycosis, proven infection was confirmed in 18 
patients, probable in 2 patients, and possible in 1 patient.
Relative IM incidence
The analysis of relative incidence of IM among all diagnosed IFD 
cases was possible for 495 PHO, 206 pediatric HCT, and 183 adult 
HCT patients, who were diagnosed with IFD at different levels 
(proven, probable, or possible) (Tab. II). When only proven diagnosis 
of IFD was taken into account, IM was diagnosed in 7.1% of all 
patients, with specific incidence of 8.1% among PHO patients, 5.4% 
among pediatric HCT patients, and 7.0% among adult HCT patients 
(p = ns; for all comparisons).
Etiology of mucormycosis
Histopathologic or microbiological diagnosis showed the presence of 
Mucor spp. in 13 patients (including 2 with probable clinical level), 
Rhizopus spp. in 4 patients (including R. mucoralis in 2 and R. oryzae 
Table I. Epidemiology of mucormycosis among all patients at risk
Groups of patients Children: PHO Children: HCT* Adults: HCT Total
Total 10/6024 5/1164 6/5237 21/12425
Allo-HCT – 5/889 6/2037 11/2926
Auto-HCT – 0/275 0/3200 0/3475
ALL 8/1317 4/293 0/348 12/1958
AML 0/295 1/171 3/1008 4/1474
NHL 1/352 0/45 0/756 1/1153
HL 0/371 0/20 1/440 1/831
CML/MPD 0/37 0/12 1/181 1/230
Other 1 (SHML)/109 (LCH) – 1 (CLL) –
* – an overlap of pediatric HCT patients with PHO patients is possible; however, PHO patients were censored at the moment of HCT; ALL – acute lymphoblastic leukemia; AML – acute 
myeloid leukemia; NHL – non-Hodgkin lymphoma; HL – Hodgkin lymphoma; CML – chronic myelogenous leukemia; MPD – myeloproliferative disease; LCH – Langerhans cell histiocytosis; 
SHML – Sinus histiocytosis with massive lymphadenopathy; CLL – chronic lymphocytic leukemia; HCT – hematopoietic cell transplantation; PHO – pediatric hemato-oncology 
Table II. Epidemiology of mucormycosis among patients diagnosed with invasive fungal disease
Groups of patients Children: PHO Children: HCT* Adults: HCT Total
Total 8/495 (1.6%) 2/206 (1.0%) 3/183 (1.6%) 13/884 (1.5%)
Allo-HCT – 2/197 (2.0%) 3/132 (2.3%) 5/329 (1.5%)
Auto-HCT – 0/24 (0.0%) 0/51 (0.0%) 0/75 (0.0%)
ALL 6/226 (2.7%) 1/58 (1.7%) 0/24 (0.0%) 7/308 (2.3%)
AML 0/84 (0.0%) 1/51 (2.0%) 2/73 (2.7%) 3/208 (1.4%)
NHL 1/33 (3.0%) 0/4 (0.0%) 0/14 (0.0%) 1/51 (2.0%)
Other 1 (SHML) – 1 (CLL) –
Level of diagnosis
Proven 6/74 (8.1%) 2/37 (5.4%) 3/43 (7.0%) 11/154 (7.1%)
Probable 2/98 (2.0%) 0/55 (0.0%) 0/49 (0.0%) 2/202 (1.0%)
Proven + probable 8/172 (4.6%) 2/92 (2.2%) 3/92 (3.3%) 11/356 (3.1%)
* – an overlap of pediatric HCT patients with PHO patients is possible; however, PHO patients were censored at the moment of HCT; ALL – acute lymphoblastic leukemia; AML – acute 
myeloid leukemia; NHL – non-Hodgkin lymphoma; HL – Hodgkin lymphoma; CML – chronic myelogenous leukemia; MPD – myeloproliferative disease; LCH – Langerhans cell histiocytosis; 
SHML – Sinus histiocytosis with massive lymphadenopathy; CLL – chronic lymphocytic leukemia
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in 1 patient), Absidia spp. (Lichtheimia corymbifera) in 2 patients, and 
Cunninghamella spp. in 1 patient (Tab. III). In 8/21 (38.1%) cases, 
coexisting IFD was diagnosed: invasive aspergillosis in 4 patients 
(3 A. fumigatus and 1 A. spp.), and invasive candidiasis in 4 patients 
(Candida albicans; C. glabrata + C. albicans; C. glabrata + C. krusei; 
C. parapsilosis).
Table III. Etiology of mucormycosis











PHO – pediatric hemato-oncology; HCT – hematopoietic cell transplantation; IM – invasive 
mucormycosis
Clinical course
Risk factors for the development of IM included neutropenia in 14 
patients and steroid therapy in 7 patients. Additionally, 4 patients 
were on other immunosuppressive therapy, 2 patients had steroid-
dependent diabetes, and 1 patient was concomitantly treated for 
CMV infection. On diagnosis of mucormycosis, 13/21 patients were 
on antifungal prophylaxis, including fluconazole in 7 patients and 
posaconazole in 6 patients – in a few cases, given sequentially with 
fluconazole (n = 2), voriconazole (n = 1), or micafungin (n = 1). Time 
to the development of IM from the beginning of chemotherapy in the 
PHO setting or from the day of transplantation in the HCT setting was 
comparable (Fig. 1).
Clinically, pneumonia was diagnosed in 10 (47.6%) patients, 
paranasal sinus involvement in 3 (14.3%) patients, gastrointestinal 
disease in 2 (9.5%) patients, and disseminated mucormycosis in 6 
(28.6%) patients.
Therapy and survival of mucormycosis
In 10 patients, antifungal monotherapy was administered, including 
sequential use of antifungals. Liposomal amphotericin B (LAmB) was 
used in 6 patients, posaconazole in 5 patients, and voriconazole 
in 1 patient (postmortem diagnosis of IM). Combination second-
line antifungal therapy was given in 11 patients: it was based on 
amphotericin B lipid complex (ABLC) in 7 cases and based on LAmB 
in 4 patients. Data on surgical treatment were available for 4 patients.
Overall, 11/21 (52.4%) patients had survived IM. Kaplan–Meier-based 
probability of survival in IM patients was 0.503 ± 0.112 (Fig. 2). IM 
IRM was 10% for pediatric nontransplant (PHO) patients and 82% for 
transplant (pediatric + adult) patients (p = 0.004). Among transplant 
patients, all adults died within 120 days, and IRM for pediatric HCT 
patients was 60% (p = 0.038) (Fig. 3).
Details on successful antifungal therapy (only children: 9 PHO and 2 
HCT patients) are presented in table IV. Overall, combination therapy 
was successful only in 3/11 patients, indicating the severity of the 
disease or failed first-line therapy.
Risk factor analysis of survival in IM patients
In univariate logistic regression of risk factor analysis of survival in 
IM patients, the following factors were analyzed: children vs. adults, 
transplant vs. nontransplant setting, clinical form, coexisting fungal 
infection, combination therapy used, use of any form of amphotericin, 
and use of LAmB vs. ABLC.
Although nonsignificant, a trend toward better outcome was observed 
in the case of sinus or gut involvement, as well as use of LAmB. No 
analysis could be performed for age groups, as all adults with IM had 
died. The only prognostic factor was HCT setting, which adversely 
influenced survival in IM patients (OR = 40; 95% CI = 3.5–530; 
p = 0.005).
Fig.1. Time to development of IM: (A) PHO vs. HCT patients, 
(B) pediatric vs. adult patients Fig. 2. Survival in 21 patients with invasive mucormycosis
A
B
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Discussion
In this study, we analyzed epidemiology, treatment, and outcome of 
IM in 12425 patients at risk. Most of the Polish HCT and pediatric 
oncology centers participated in the study, with period of inclusion 
ranging from 3 to 6 years, rendering the results of important value.
We have shown that proven IM was diagnosed in 7.1% of all patients 
with IFD, as well as in specific subgroups: 8.1% among PHO patients, 
5.4% among pediatric HCT patients, and 7.0% among adult HCT 
patients. These results are comparable with other reports [1, 14]; 
Leventakos et al. [15] even indicated an increase in relative incidence 
of IM up to 9% in an autopsy study.
In our material, Mucor spp. was the most frequently (70%) diagnosed 
species in hematological patients, while in European material, it was 
Rhizopus spp. (34%). Absidia and Cunninghamella were relatively 
rare in both our sample and the European material [16]. Similar 
to other data, the most frequent clinical type was pulmonary or 
disseminated disease.
Probability of overall survival in IM patients was 0.50 ± 0.11. This is 
a much better result than the results from studies performed a decade 
Fig. 3. Survival in IM patients and infection-related mortality in mucormycosis: (A, B) in PHO vs. HCT (children + adult) patients, 
(C, D) in HCT children vs. adult HCT patients
Table IV. Successful antifungal therapy
Patient Clinical form Antifungal therapy
1 Paranasal sinuses^ LamB + Posaconazole*
2 Paranasal sinuses^ LAmB, Posaconazole, ABLC, Posaconazole 
3 Pulmonary Posaconazole
4 Pulmonary Voriconazole, Caspofungin + ABLC*, Isavuconazole
5 Disseminated Voriconazole, Posaconazole, LAmB
6 Gastrointestinal LAmB
7 Pulmonary LAmB
8 Pulmonary Voriconazole + ABLC*, Posaconazole
9 Pulmonary Voriconazole, LAmB
10 Gastrointestinal Posaconazole
11 Paranasal sinuses LAmB
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ago [5, 16, 17] and is comparable with recent reports [6, 7, 18]. Still, the 
outcome is much worse than in immunosuppressed patients infected 
with invasive aspergillosis or invasive candidiasis. However, it 
should be underlined that the outcome for pediatric patients, both 
transplant and nontransplant, was much better, reaching 90% in 
nontransplant patients. Good outcome was seen in cases of gut or 
paranasal sinus involvement, although the number of patients with 
such presentation was small.
Introduction of the national program of antifungal prophylaxis with 
posaconazole in 2014–2015 has already resulted in a decrease 
of IFD cases for the following groups of patients – patients with 
high-risk acute leukemia, HCT patients with neutropenia and 
GVHD, and patients in secondary prophylaxis. On the other 
hand, voriconazole, the other antifungal agent frequently used in 
prophylaxis, could influence the rate of IM, since the spectrum of 
activity of this azole does not cover Mucorales.
In the majority of patients with positive outcome of IM, treatment 
was based on the use of LAmB, although other drugs or 
combinations were also successful in individual cases (Tab. IV). 
Recent data indicate that isavuconazole is another important 
antifungal agent with activity against Mucorales [18, 19, 20]. 
Several recent meta-analyses have also addressed the topic of 
mucormycosis [21-24].
The limitations of the study include the following: different periods 
of inclusion of specific centers, limited possibility of diagnosis 
of IM with PCR in some of the centers, and limited number of 
biopsies performed in case of suspicion of IFD. We are aware that 
the incidence of IM could possibly be underdiagnosed, as there 
are no biomarkers available and Mucor-directed PCR has become 
available only recently in Poland. The diagnosis of IM in clinical 
practice is based on biopsy only, as this invasive procedure is not 
frequently performed in HCT patients and in children with HMs.
Conclusions
Current data from Polish pediatric and adult HCT centers as 
well as pediatric oncology centers, show the incidence of IM at 
the rate of 7.1% of all proven cases of IFD. The most frequent 
species are Mucor spp. and Rhizopus spp. Clinically, pulmonary 
or disseminated mucormycosis presented in 75% of all cases. 
Although no statistical analysis could be performed, most of the 
IM cases occurred among allo-HCT, pediatric acute lymphoblastic 
leukemia, and adult acute myeloid leukemia patients. The outcome 
of IM is dismal, particularly in patients after allo-HCT; however, 
treatment of IM in nontransplant children resulted in 90% success. 
The use of LAmB – and in individual cases, posaconazole, ABLC, 
or isavuconazole – contributed to positive outcome and survival 
in IM patients. Finally, the incidence and outcome of IM in Polish 
post-HCT patients and in Polish children treated for malignancy 
are similar to European data.
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